Use of transcriptomic signatures of <i>RAD51</i> and <i>GATA6</i> to predict real-world overall survival with platinum therapy in <i>BRCA/PALB2</i> wild-type metastatic pancreatic cancer.
Binbin Zheng-Lin(WinnMed), Tanios S. Bekaii-Saab(WinnMed), T. Yoshino(National Cancer Center Hospital East), Unnati Jariwala, Oluseyi Abidoye(Mayo Clinic), Taro Shibuki(National Cancer Center Hospital East), Mitesh J. Borad(Jacksonville College), Jeremy Jones(Mayo Clinic in Florida), Cody Eslinger(WinnMed), John Strickler(Duke Medical Center), Ellen Jaeger(Tempus Labs (United States)), Matina Fragkogianni(Tempus Labs (United States)), Arya Ashok(Tempus Labs (United States)), Kayla Viets Layng(Tempus Labs (United States)), D. Ahn(WinnMed), Celine Hoyek(Mayo Clinic Hospital), Christina Wu(WinnMed), Masafumi Ikeda(National Cancer Center Hospital East), Mohamad Bassam Sonbol(WinnMed), Angelo Pirozzi(Humanitas University)
Cited by 0
Related Papers
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
|Cell Reports|2017|619
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
<sup>Non-V600</sup><i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2017|357